August 30, 2016
(Genetic Engineering & Biotechnology News) – The recent regulatory approval of the first hematopoietic stem and progenitor cell gene therapy (HSPC-GT) signals the start of a new era for gene therapy and highlights the potential contribution by high-throughput cell culture technologies in propelling HSPC-GT from curing rare diseases to curing more common diseases. Hematopoietic stem cells (HSCs) are the “fountain” for all blood cells that circulate in our bodies throughout life. Arguably, no other cell type has more profound and far-reaching influence on our well-being than HSCs.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.